title: Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer.
abstract: Chemoradiotherapy has become the standard treatment for patients with locally advanced non-small-cell lung cancer on the basis of several large randomized trials. Despite an increase in median survival from 10 months with radiotherapy alone to 16 to 17 months with concurrent chemoradiotherapy, long-term survival in this disease remains modest at best. With the advent of new biologic agents targeting specific cellular pathways associated with malignant progression, combined-modality therapy has the potential to target tumors selectively with less toxicity.
authors.affiliation: Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, B902 TVC, 22nd Avenue South, Nashville, TN 37232-5671, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: MacRae
authors.forename: Hak
authors.initials: H
authors.lastname: Choy
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D019452:Terminally Ill; D016896:Treatment Outcome